Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis

Abstract

A composition comprising a powder mixture of potassium citrate and calcium citrate as mixtures of pure chemical salts and methods of making and using the composition are disclosed. The composition is useful for the treatment and prevention of kidney stones and osteoporosis and better delivers potassium and calcium than commonly used potassium and calcium supplements.

1 . A composition comprising a mixture of potassium citrate, citric acid and a component selected from the group consisting of calcium carbonate, calcium hydroxide, calcium oxide and any combination thereof.  
     
     
         2 . The composition of  claim 1 , wherein said mixture is a powder mixture.  
     
     
         3 . The composition of  claim 1 , wherein the potassium citrate is at a level of from about 10 mEq to about 40 mEq, the calcium carbonate is at a level of from about 10 mEq to about 40 mEq, and citric acid is at a level of from about 20 mEq to about 100 mEq.  
     
     
         4 . The composition of  claim 1 , wherein said composition comprises about 20 mEq potassium citrate, about 20 mEq calcium carbonate, and about 20 mEq citric acid.  
     
     
         5 . The composition of  claim 4 , having an additional 0.17-1.34 mEq of citrate in the form of citric acid.  
     
     
         6 . The composition of  claim 1 , further comprising a sweetener.  
     
     
         7 . The composition of  claim 6 , wherein said sweetener is an artificial sweetener.  
     
     
         8 . The composition of  claim 1 , wherein the composition is in the form of a solution.  
     
     
         9 . The composition of  claim 8 , wherein the solution is an aqueous solution.  
     
     
         10 . The composition of  claim 1 , wherein the composition is in the form of a suspension.  
     
     
         11 . A powder mixture comprising potassium citrate, calcium carbonate and citric acid which when dissolved in water yields an aqueous solution of potassium, calcium and citrate at a molar ratio of potassium:calcium:citrate in a range of 2:1:1.33 to 2:1:2.67.  
     
     
         12 . The powder mixture of  claim 11 , wherein the potassium citrate is at a level of from about 10 mEq to about 40 mEq, the calcium carbonate is at a level of from about 10 mEq to about 40 mEq, and citric acid is at a level of from about 20 mEq to about 100 mEq.  
     
     
         13 . The powder mixture of  claim 12 , comprises about 20 mEq potassium citrate, about 20 mEq calcium carbonate, and about 20 mEq citric acid.  
     
     
         14 . The powder mixture of  claim 12 , having an additional 0.17-1.34 mEq of citrate in the form of citric acid.  
     
     
         15 . The powder mixture of  claim 11 , having a molar ratio of potassium:calcium:citrate of 2:1:1.33.  
     
     
         16 . A method of treating or preventing osteoporosis or kidney stones or both in an animal comprising the administration of a composition comprising a mixture of potassium citrate, citric acid and a component selected from the group consisting of calcium carbonate, calcium hydroxide, calcium oxide and any combination thereof, said composition having a molar ratio of potassium:calcium:citrate in a range of from 2:1:1.33 to 2:1:2.67.  
     
     
         17 . The method of  claim 16 , wherein the animal is human.  
     
     
         18 . The method of  claim 17 , wherein the human is a postmenopausal woman.  
     
     
         19 . The method of  claim 16 , wherein said administration comprises oral administration.  
     
     
         20 . The method of  claim 16 , wherein the animal has chronic diarrheal syndrome.  
     
     
         21 . The method of  claim 16 , wherein the composition has a molar ratio of potassium:calcium:citrate of 2:1:1.33.  
     
     
         22 . A method of treating or preventing osteoporosis or kidney stones or both in an animal comprising the administration of a composition comprising a mixture of potassium citrate and calcium citrate having a molar ratio of potassium:calcium:citrate in a range of from 2:1:1.33 to 2:1:2.67.  
     
     
         23 . The method of  claim 22 , wherein the animal is human.  
     
     
         24 . The method of  claim 23 , wherein the human is a post-menopausal woman.  
     
     
         25 . The method of  claim 22 , wherein said administration comprises oral administration.  
     
     
         26 . The method of  claim 22 , wherein the animal has chronic diarrheal syndrome.  
     
     
         27 . The method of  claim 22 , wherein the composition has a molar ratio of potassium:calcium:citrate of 2:1:1.33.